News Releases

Month Year

Month Year

Investor Alerts

May 30, 2023

IDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events
May 26, 2023

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 22, 2023

IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors
May 16, 2023

IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma
May 9, 2023

IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
May 1, 2023

IDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event
Apr 28, 2023

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apr 27, 2023

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Apr 24, 2023

IDEAYA Announces Pricing of Public Offering
Apr 24, 2023

IDEAYA Announces Proposed Public Offering of Common Stock
Apr 23, 2023

IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma
Apr 19, 2023

IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors
Apr 3, 2023

IDEAYA Biosciences to Participate in Upcoming April 2023 Investor Relations Event
Mar 31, 2023

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mar 14, 2023

IDEAYA Announces Presentations at AACR Annual Meeting 2023 for Potential First-in-Class Synthetic Lethality Programs IDE397 (MAT2A), IDE161 (PARG) and Werner Helicase
Mar 7, 2023

IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update
Mar 1, 2023

IDEAYA Biosciences to Participate in Investor Conferences in March 2023
Feb 16, 2023

IDEAYA Biosciences to Participate in Citi's 2023 Virtual Oncology Leadership Summit
Feb 1, 2023

IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference
Jan 23, 2023

IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma
Jan 9, 2023

IDEAYA Announces IND Clearance by U.S. FDA enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161
Jan 3, 2023

IDEAYA Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
Dec 19, 2022

IDEAYA Biosciences Appoints Dr. Karlene Cimprich, Ph.D. and Dr. Kornelia Polyak, M.D., Ph.D. to Scientific Advisory Board
Dec 12, 2022

IDEAYA Biosciences Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161
Dec 5, 2022

IDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma

Show per page